Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib plus vildagliptin in relapsed treatment-free remission chronic myeloid leukemia
NL-OMON55403Phase 2Completed
- Sponsor
- Albert Schweitzer Hospital
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nilotinib and vildagliptin in chronic myelogenous leukemia (CML), sponsored by Albert Schweitzer Hospital. Primary endpoints: Dose-limiting toxicity of vildagliptin with nilotinib and Reduction in Ph+ CD34+ CD38- CD26+ bone marrow cells. Started Sep 2018; status: completed.
02
Drugs
nilotinibvildagliptin
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON55403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55403.